180 Life Sciences rebranded to ETHZilla, raising 425 million USD to purchase Ethereum

The biotechnology company listed on Nasdaq — 180 Life Sciences — is making a bold shift to crypto, with plans to rename itself ETHZilla and move all of its reserve assets to Ethereum.

The company announced that it has reached a private funding agreement worth 425 million USD, led by top funds in the Ethereum ecosystem such as Electric Capital, Polychain, along with the founders of Lido, Eigenlayer, and Compound. The deal is expected to be completed on August 1.

ETHZilla will not only store ETH but also actively participate in DeFi strategies such as staking, providing liquidity, and lending, with a portfolio managed by Electric Capital.

This move marks a significant turning point, from a company researching arthritis drugs to a large-scale Ethereum treasury for businesses, right as companies begin to rush into ETH. According to Standard Chartered, corporate treasuries have held more than 1% of the ETH supply, and it could increase to 10% in the future.

ETH-1.11%
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Share
Comment
0/400
No comments
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate app
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)